Koers Genmab Nasdaq Copenhagen
Aandelen
DK0010272202
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 19,79 mld. 2,85 mld. 2,65 mld. | Omzet 2025 * | 23,61 mld. 3,4 mld. 3,16 mld. | Marktkapitalisatie | 129 mld. 18,64 mld. 17,33 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 4,67 mld. 673 mln. 626 mln. | Nettowinst (verlies) 2025 * | 6,65 mld. 959 mln. 891 mln. | EV/omzet 2024 * | 5,22 x |
Nettoliquiditeiten 2024 * | 26,11 mld. 3,76 mld. 3,5 mld. | Nettoliquiditeiten 2025 * | 33,02 mld. 4,76 mld. 4,42 mld. | EV/omzet 2025 * | 4,08 x |
K/w-verhouding 2024 * |
29,2
x | K/w-verhouding 2025 * |
21
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,51% |
Recentste transcriptie over Genmab
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 63 | 01-01-99 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 01-01-07 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 23-03-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 01-01-17 |
Director/Board Member | 73 | 01-11-03 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 01-01-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+2,93% | 106 mld. | |
+7,02% | 23,47 mld. | |
-14,60% | 21,9 mld. | |
-38,55% | 17,85 mld. | |
-8,83% | 16,78 mld. | |
+5,51% | 14,41 mld. | |
+37,49% | 12,86 mld. | |
+329,39% | 8,78 mld. | |
-24,02% | 8,37 mld. |